Clinical Oncology
Volume 16, Issue 8 , Pages 543-548 , December 2004

The use of topotecan for relapsed ovarian cancer in accordance with the National Institute for Clinical Excellence guidance 2001: the Nottingham experience

  • A. Anand
    • ,
  • S.Y. Chan

      Affiliations

    • Corresponding Author InformationAuthor for correspondence: Dr Stephen Y. Chan, Department of Clinical Oncology, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. Tel: +44-115-9691169, ext 47298; Fax: +44-115-9628047.

Received 22 December 2003 ,Revised 22 June 2004 ,Accepted 6 July 2004.

References 

  1. American Cancer Society . Statistics for 2003. Cancer facts and figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdfaccessed 16 May 2003
  2. Eltabbakh GH, Yadav PR, Morgan A, et al. Clinical picture of women with early stage ovarian cancer. Gynecol Oncol. 1999;75:476–479
  3. Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–2075
  4. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: principles and practice of oncology. 5th edn. Philadelphia, PA: Lippincott-Raven; 1997;p. 1502–1539
  5. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  6. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708
  7. Hilkens PH, Pronk LC, Verweij J, et al. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997;75:417–422
  8. International Collaborative Ovarian Cancer Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002;505–515
  9. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–2193
  10. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–3322
  11. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist. 1999;4:87–94
  12. Kavanagh H, Tresukosol D, Edwards C, et al. Carboplatin reinduction after taxane in patients with platinum refractory epithelial ovarian cancer. J Clin Oncol. 1995;13:1584–1588
  13. National Institute for Clinical Excellence . Guidance on the use of topotecan for the treatment of advanced ovarian cancer. London: National Institute for Clinical Excellence; 2001;http://www.nice.org.uk/pdf/topotecanguidance.pdfaccessed 16 May 2003
  14. National Institute for Clinical Excellence . Guidance on the use of pegylated liposomal doxorubicin hydrochloride (PLDH) for the treatment of advanced ovarian cancer. London: National Institute for Clinical Excellence; 2002;http://www.nice.org.uk/pdf/Fullguidance-PDF-ovariancancer.pdfaccessed 16 May 2003
  15. Creel J. Cancer care at home: past, present, and future. Caring. 1996;15:24–26
  16. Otsuka A, Ono S, Hata M, et al. Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma. [in Japanese] Gan To Kagaku Ryoho. 1997;24(suppl 4):485–489
  17. Holdsworth MT, Raisch DW, Chavez CM, et al. Economic impact with home delivery of chemotherapy to pediatric oncology patients. Ann Pharmacother. 1997;31:140–148
  18. WHO . WHO handbook for reporting results of cancer treatment. Geneva: WHO; 1979;
  19. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  20. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol. 1996;14:1545–1551
  21. Cesano A, Lane S, Poulin R, et al. Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol. 1999;15:1233–1238
  22. Morris R, Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist. 2002;7:29–35
  23. Armstrong D, O'Reilly S. Clinical guidelines for managing topotecan-related hematologic toxicity. Oncologist. 1998;3:4–10
  24. Koppel RA, Boh EE. Cutaneous reactions to chemotherapeutic agents. Am J Med Sci. 2001;321:327–335
  25. Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer. Gynecol Oncol. 2001;83:257–262
  26. Forbes C, Wilby G, Richardson G, et al. A rapid and systematic review of the clinical effectiveness and cost effectiveness of pegylated liposomal doxorubicin hydrochloride (Caelyx® UK, Doxil® USA) for ovarian cancer. Assessment report prepared for the NHS R&D HTA Programme by the NHS Centre for Reviews and Dissemination, Centre for Health Economics, University of York, UK, 21 November, 2001. http://www.nice.org.uk/pdf/caelyxassessmentreport.pdfaccessed 16 May 2003

PII: S0936-6555(04)00258-4

doi: 10.1016/j.clon.2004.07.003

Clinical Oncology
Volume 16, Issue 8 , Pages 543-548 , December 2004

Article Tools